Project Description

CEO: Mark A. Emalfarb
Headquarters: Jupiter, Florida
October 2004
APO Financing: $25,405,000
Trading Venue: OTCQX (DYAI)

We are a global biotechnology company with patented and proprietary technologies that are used to discover, develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic’s C1 platform technology enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. Dyadic leverages the value of its technologies through licensing arrangements and other collaborations with third parties who receive the benefits of producing and using the proteins these technologies help produce.